SLC5A2 and type 2 diabetes mellitus: The initial finding that SGLT2 inhibitors significantly reduced morbidity and mortality in patients with T2D (Wiviott et al., 2019; Zinman et al., 2015) was followed by discovery that these benefits extended to heart failure (HF) patients without T2D.